Background. Intravenous immunoglobulin (IVIG) has been utilized in several
forms of vasculitis and has many potential mechanisms of action, including
the inhibition of C3 activation. We have previously demonstrated that IVIG
can reduce glomerular injury in a model of membranous nephropathy mediated
by C5b-9 [1]. C5b-9 has also been shown to mediate the thrombotic microangi
opathy (TMA) induced by antibody to glomerular endothelial cells leading to
a hemolytic uremic syndrome-type lesion [2].
Methods. To test the hypothesis that IVIG might be effective in treating an
tibody-induced TMA, male uninephrectomized rats underwent right renal arter
y perfusion with goat anti-rat glomerular endothelial cell (GEN) antibody (
20 mg/kg). Sheep IgG (200 mg/kg) was administered either 30 minutes before
the renal artery perfusion (group I, N = 6) or 30 minutes postperfusion (gr
oup II, N = 9). A third control group received phosphate-buffered saline (P
BS; group III, N = 12). A survival biopsy was performed at 15 minutes, and
the animals were sacrificed on day 2.
Results. There were no significant differences in proteinuria or hematocrit
between the groups. Animals pretreated with IVIG had significantly improve
d survival and renal function, which was associated with a decrease in glom
erular C3 deposition. The protective effect of IVIG was abolished if the ad
ministration was delayed 30 minutes after perfusion.
Conclusions. IVIG is effective in reducing injury in experimental TMA only
if given prophylactically. The effect is mediated by inhibition of local in
traglomerular complement activation.